| Identification | More | [Name]
2,4-Dichloro-6,7-dimethoxyquinazoline | [CAS]
27631-29-4 | [Synonyms]
2,4-DICHLORO-6,7-DIMETHOXYQUINAZOLINE
TIMTEC-BB SBB000972
2,4-Dichloro-6,7-dimethoxyquin
2,4-DICHLORO-6,7-DIMETHOXYQUINAZOLINETERAZOSIN
2,4-Dichloro-6,7-dimethoxyquinazoline, 98+%
2,4-Dichloro-6,7-dimethoxyxinazoline
2,4-Dichloro-6-methoxy-7-quinazolinyl methyl ether ,98%
2,4-Dichloro-6,7-dimethoxyquinoazoline | [EINECS(EC#)]
608-117-4 | [Molecular Formula]
C10H8Cl2N2O2 | [MDL Number]
MFCD00051733 | [Molecular Weight]
259.09 | [MOL File]
27631-29-4.mol |
| Chemical Properties | Back Directory | [Appearance]
pale yellow to beige crystalline powder | [Melting point ]
175-178 °C (lit.) | [Boiling point ]
340.5±42.0 °C(Predicted) | [density ]
1.5369 (rough estimate) | [refractive index ]
1.6100 (estimate) | [storage temp. ]
2-8°C | [solubility ]
Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly) | [form ]
Crystalline Powder | [pka]
-0.49±0.30(Predicted) | [color ]
Pale yellow to beige | [Water Solubility ]
Insoluble in water. | [Sensitive ]
Moisture Sensitive | [Detection Methods]
HPLC,NMR | [BRN ]
190331 | [CAS DataBase Reference]
27631-29-4(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S37/39:Wear suitable gloves and eye/face protection .
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36:Wear suitable protective clothing . | [WGK Germany ]
3 | [HS Code ]
29334900 |
| Hazard Information | Back Directory | [Chemical Properties]
pale yellow to beige crystalline powder | [Uses]
2,4-Dichloro-6,7-dimethoxyquinazoline is used as an intermediate in the preparation of potential inhibitors of epidermal growth factor receptor kinases. It is also used as an intermediate in the preparation of terazosin. | [Uses]
An intermediate in the preparation of potential inhibitors of epidermal growth factor receptor kinases. An intermediate in the preparation of Terazosin (T105000). | [Synthesis]
The general procedure for the synthesis of 2,4-dichloro-6,7-dimethoxyquinazoline from 6,7-dimethoxy-2,4-quinazolinedione was as follows: in a 100 mL three-necked flask equipped with a reflux condenser, 6,7-dimethoxy-2,4-quinazolinedione (1.00 g) and phosphorus triclosan (15 mL; 24.77 g; 161.53 mmol) were added, the reaction mixture was refluxed at 100 °C in an oil bath with stirring for 24 hours. Upon completion of the reaction, the reaction solution was cooled to room temperature and the reaction was quenched by slowly pouring it into an ice-water mixture under vigorous stirring. The precipitated solid was collected by vacuum filtration and the crude product was purified by silica gel column chromatography using dichloromethane as eluent. | [References]
[1] Journal of Medicinal Chemistry, 1986, vol. 29, # 5, p. 627 - 629
[2] European Journal of Medicinal Chemistry, 2014, vol. 71, p. 1 - 14
[3] Patent: WO2004/13091, 2004, A2. Location in patent: Page 34-35
[4] The Journal of organic chemistry, 2002, vol. 67, # 23, p. 8284 - 8286
[5] Journal of the Chemical Society, 1948, p. 1759,1765 |
|
|